We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA on Thursday released final guidance on how the agency will weigh the legally required factors when considering whether to require a risk evaluation mitigation strategy for medicines.